GW Pharmaceuticals PLC (NASDAQ:GWPH) was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday.

Other equities analysts also recently issued research reports about the stock. Maxim Group reissued a “buy” rating and set a $135.00 target price on shares of GW Pharmaceuticals PLC in a research note on Thursday, May 25th. Zacks Investment Research downgraded shares of GW Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research note on Monday, May 15th. BidaskClub raised shares of GW Pharmaceuticals PLC from a “strong sell” rating to a “sell” rating in a research note on Wednesday, June 14th. TheStreet downgraded shares of GW Pharmaceuticals PLC from a “c-” rating to a “d+” rating in a research note on Wednesday, May 10th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $208.00 target price on shares of GW Pharmaceuticals PLC in a research note on Tuesday, May 9th. Two analysts have rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $144.50.

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Shares of GW Pharmaceuticals PLC (GWPH) traded up 0.47% during mid-day trading on Wednesday, hitting $104.72. The company had a trading volume of 327,279 shares. The firm’s 50-day moving average price is $103.62 and its 200 day moving average price is $115.89. The company’s market capitalization is $2.65 billion. GW Pharmaceuticals PLC has a one year low of $79.62 and a one year high of $137.88.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last announced its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.50) by $0.20. GW Pharmaceuticals PLC had a negative return on equity of 22.81% and a negative net margin of 1,021.38%. The firm had revenue of $2.04 million for the quarter, compared to the consensus estimate of $2.07 million. During the same period in the prior year, the business earned ($0.06) EPS. GW Pharmaceuticals PLC’s quarterly revenue was down 23.0% on a year-over-year basis. Analysts predict that GW Pharmaceuticals PLC will post ($5.34) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “GW Pharmaceuticals PLC (GWPH) Upgraded to Hold at ValuEngine” was originally reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/06/21/gw-pharmaceuticals-plc-gwph-upgraded-to-hold-at-valuengine.html.

Large investors have recently bought and sold shares of the company. Rothschild Investment Corp IL boosted its stake in GW Pharmaceuticals PLC by 2.7% in the first quarter. Rothschild Investment Corp IL now owns 10,437 shares of the biopharmaceutical company’s stock worth $1,262,000 after buying an additional 272 shares during the last quarter. Bank of Montreal Can boosted its stake in GW Pharmaceuticals PLC by 2,419.0% in the first quarter. Bank of Montreal Can now owns 2,519 shares of the biopharmaceutical company’s stock worth $305,000 after buying an additional 2,419 shares during the last quarter. Creative Planning boosted its stake in GW Pharmaceuticals PLC by 179.3% in the first quarter. Creative Planning now owns 2,497 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 1,603 shares during the last quarter. Vident Investment Advisory LLC bought a new stake in GW Pharmaceuticals PLC during the fourth quarter worth approximately $334,000. Finally, United Capital Financial Advisers LLC boosted its stake in GW Pharmaceuticals PLC by 13.9% in the fourth quarter. United Capital Financial Advisers LLC now owns 2,112 shares of the biopharmaceutical company’s stock worth $236,000 after buying an additional 257 shares during the last quarter. Institutional investors and hedge funds own 75.65% of the company’s stock.

GW Pharmaceuticals PLC Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.